I-3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Ukuhlanzeka >99.0% I-Lenalidomide Intermediate Factory
I-Ruifu Chemical ingumkhiqizi ohamba phambili we-3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) enekhwalithi ephezulu, ephakathi kwe-Pomalidomide (CAS: 19171-19-8).I-Ruifu Chemical inganikeza ukulethwa komhlaba wonke, intengo encintisanayo, isevisi enhle kakhulu, amanani amancane kanye nenqwaba etholakalayo.Thenga i-3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Igama Lekhemikhali | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Omqondofana | I-3-Aminopiperidine-2,6-Dione HCl;I-3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Inombolo ye-CAS | 24666-56-6 |
| I-CAS ehlobene | 2686-86-4;25181-50-4 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
| I-Molecular Formula | I-C5H9ClN2O2 |
| Isisindo samangqamuzana | 164.59 |
| I-Melting Point | 120℃ |
| I-COA ne-MSDS | Iyatholakala |
| Umsuka | Shanghai, China |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | I-Off-White Crystalline Powder |
| Ukuhlanzeka / Indlela Yokuhlaziya | >99.0% (HPLC) |
| Umswakama (KF) | <0.50% |
| Ukulahlekelwa Ekumisweni | <0.50% |
| Izinsalela ekushiseni | <0.20% |
| Ukungcola Okuphelele | <1.00% |
| I-Infrared Spectrum | Ivumelana Nesakhiwo |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-Intermediate ye-Lenalidomide (CAS: 191732-72-6) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) iphakathi kokulungiselela iLenalidomide (CAS: 191732-72-6).I-Lenalidomide iwuhlobo lwemithi elwa nesimila eyakhiwa izinkampani zemithi yebhayoloji yaseMelika.Inemisebenzi eminingi efana ne-anti-tumor, i-immune regulation kanye ne-anti-angiogenesis.Ingavimbela ukukhiqizwa kwama-cytokines avuthayo, futhi ikhulise ukugcinwa kwe-peripheral blood mononuclear anti-inflammatory cytokines.Ingavimbela ukukhula kwamaseli amaningi e-myeloma eziguli kanye neseli le-MM1S.Ucwaningo lwemitholampilo olulawulwa yi-placebo olunama-multicenter randomized double-blind blind-blind luhlola ukuphepha nomphumela wokwelapha we-lenalidomide esetshenziselwa i-myeloma eminingi.Imiphumela yakamuva yocwaningo lomtholampilo ibonisa ukuthi i-lenalidomide ayinawo umphumela wokwelapha ekwelapheni i-MDS ne-MM kuphela, kodwa futhi ekwelapheni i-myeloma, i-leukemia, i-metastatic renal cell carcinoma, isimila esiqinile, i-idiopathic generalized amyloidosis kanye nesifo se-systemic bone marrow fibrosis esinomnkantsha ongavuthiwe.NgoDisemba 2005, i-US Food and Drug Administration (FDA) yagunyaza i-lenalidomide ukuthi isetshenziselwe ukwelapha i-myelodysplastic syndrome (MDS).
